As the 2025-2026 flu season approaches, public health officials and vaccine manufacturers have finalized their strategy to combat circulating influenza viruses.
This year’s vaccine introduces an updated composition and notable developments in vaccine administration and availability, reinforcing the importance of annual vaccination for all eligible individuals.
The Shift to Trivalent Vaccines
A major update for the upcoming season is the composition of the vaccine in the Northern Hemisphere (e.g., the U.S. and Europe). Following the sustained, low-to-absent circulation of the Influenza B/Yamagata lineage virus since early 2020, regulatory bodies have recommended a transition from quadrivalent (four-component) to trivalent (three-component) vaccines as the standard for the season.
The 2025-2026 trivalent formulation is designed to protect against the three most prevalent flu virus groups currently circulating:
-
An Influenza A(H1N1)pdm09-like virus
-
An updated Influenza A(H3N2)-like virus (a change from the previous season)
-
An Influenza B/Victoria lineage-like virus
This shift to a trivalent vaccine maintains high efficacy against the viruses most likely to cause illness, without including a component that is no longer a significant threat.
Expanded Access and New Approvals
Access and options for vaccination are also seeing important updates:
Self- or Caregiver-Administration of Nasal Spray: The live attenuated influenza vaccine (LAIV), commonly known as the nasal spray, has received approval for self-administration or caregiver administration in eligible populations (generally ages 2–49). This new option is anticipated to simplify the vaccination process for those who prefer the nasal spray formulation and are within the approved age range.
Broader Age Range for Recombinant Vaccine: The recombinant influenza vaccine (RIV3), a non-egg-based option, has been approved for a younger population, now recommended for individuals starting at 9 years of age (down from ≥18 years). This provides a preferred non-egg-based choice for a wider range of children and adolescents.
Focus on Single-Dose Formulations: Health authorities have also placed a strong emphasis on using single-dose formulations that are free of thimerosal as a preservative for most populations, including children and pregnant women.
Annual Vaccination Remains Key
The core recommendation remains unchanged: Annual influenza vaccination is recommended for everyone ≥6 months of age who does not have a contraindication.
Important Timing Considerations:
Most Adults and Pregnant Women (1st/2nd Trimester): The optimal time for vaccination continues to be September or October to ensure protection covers the peak of the flu season.
Pregnant Women (3rd Trimester): Vaccination during July or August may be considered to maximize antibody transfer to the baby, offering protection in the first months of life.
Children Requiring Two Doses: Children aged 6 months through 8 years who require two doses (i.e., those who are first-time recipients or whose vaccination history is incomplete) should receive their first dose as soon as the vaccine is available (including July/August) to allow the second dose to be administered four weeks later, ideally completing the series by the end of October.
Vaccination is a critical step in preventing flu-related hospitalizations and severe complications. By staying informed about this season’s changes and getting vaccinated promptly, individuals can best protect their health and the health of their communities.